Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PsiOxus Therapeutics Ltd.

Division of Psioxus Therapeutics Ltd.
www.psioxus.com

Latest From PsiOxus Therapeutics Ltd.

Touchstone Plays Tough As IP Group Ups Bid To £490m

One of the key attractions is Touchstone's holdings in Imperial College spin-offs such as Cell Medica, Circassia Pharmaceuticals and TopiVert Pharma.

M & A Intellectual Property

BIO Notebook, Day 4: Annual Convention Winds Down With Oncology In The Spotlight

Oncology was top of mind for Scrip on the final day of the BIO International Convention in San Diego, including a next-generation cancer drug panel discussion and interviews with novel therapeutic developers. A day earlier, we spoke with Merck & Co about deals related to Keytruda and beyond.

ImmunoOncology Business Strategies

Can Drugs Really Treat Sarcopenia? Some Patients Are Doubtful

Companies developing treatments for sarcopenia ‘have no idea what they're doing’, according to Ray Lipicky, a former director of the FDA’s Cardio-Renal Drug Products Division who spoke as a patient at the US agency’s sarcopenia drug development meeting.

Regulation Drug Approval Standards

Deals Shaping the Medical Industry, January 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Transgenics
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Psioxus Therapeutics Ltd.
  • Senior Management
  • John Beadle, MD, CEO
    Theodora Harold, CFO & Secretary
    Hilary McElwaine-Johnn, MD, CMO
    Charles Morris, Chief Dev. Officer
    Karen LaRochelle, CBO
  • Contact Info
  • PsiOxus Therapeutics Ltd.
    Phone: (44) 1235 835328
    154B Brook Dr., Milton Park
    Abingdon
    Oxfordshire, OX14 4SD
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register